Welcome to the second Diagnostics Accelerator Investigators’ Meeting!
Since its 2018 launch, the Diagnostics Accelerator (DxA) has fostered a bold vision of setting a new gold standard for non-invasive and affordable biomarkers for the early diagnosis of Alzheimer’ disease and related dementias. The recent approval of aducanumab demonstrates
the value of biomarkers in clinical trials and the need for a low-cost, non-invasive way to identify the right patients for disease modifying treatment. However, due to the heterogeneity of the disease, the best approach to diagnosing and treating Alzheimer’s and other neurodegenerative diseases will likely require a combination approach involving multiple biological pathways. The Diagnostics Accelerator has striven for a diverse portfolio of emerging biomarkers to assess the different facets of disease more fully. The goal is precision medicine for neurodegenerative disease.
This year’s investigators’ meeting promises to be another exciting opportunity for DxA-funded researchers to share their research and discuss the work of others on fluid, ocular, and digital biomarkers. And with investments made to a diverse group of more than three dozen researchers globally, we are sure you will be as amazed as we are at the ingenuity on display.
Over the next three days of this hybrid meeting, we will welcome participants both in-person and virtually and will hear from leading academic scientists, entrepreneurs, startup companies, funding organizations, and others who are part of this collaborative effort.
Here is some of what to expect this year:
- Data-driven updates from our earliest funded investigators
- Updates on digital biomarker projects
- Posters from more recently funded investigators to allow for in-depth review of study design, rationale and planned work
- Expert panels and in-depth Q&A sessions
- Virtual breakout rooms to foster collaboration and interaction between DxA investigators, funders and pharma partners
As always, we are grateful for the vision and support of ADDF’s Co-Founder/Co-Chair Leonard A. Lauder and Bill Gates and all the core funders, including the Dolby family, the Charles and Helen Schwab Foundation, Jeff Bezos, MacKenzie Scott, The Association for Frontotemporal
Degeneration, and others to bring the focus, resources and urgency required to advance the development of diagnostic tools.
We hope that you all will take this opportunity to connect with your fellow investigators so we can all learn from one other and exchange ideas to further accelerate everyone’s research and the field as a whole.
We look forward to a thought-provoking and insightful meeting.
|Howard Fillit, MD
Founding Executive Director and Chief Science Officer
Alzheimer’s Drug Discovery Foundation
|Niranjan Bose, PhD
Managing Director of Health & Life Sciences
These awards focus on true collaboration among renowned clinicians, who are directly involved in patient care and understand the disease, scientists who are developing the tests, and diagnostics companies that understand the regulatory pathways – driving research and product development.
25 Podium Presentations
13 Virtual Poster Presentations
Virtual and Live Q&A
Access to meeting by invitation only
Part 1: ATN Biomarkers
Part 2: Ocular Approaches and Emerging Protein Biomarkers of ADRD
Part 1: Peripheral Molecular Biomarkers of ADRD
Part 2: Misfolded Proteins and Biomarkers of FTD
Part 3: Updates from the Pacific Rim
Monday, October 11, 2021
10:00 – 17:30 US Eastern Time
Tuesday, October 12, 2021
10:00 – 15:15 US Eastern Time
18:00 – 19:15 US Eastern Time
Wednesday, October 13, 2021
9:00 – 10:00 US Eastern Time – Meet with DxA Team
10:00 – 12:30 US Eastern Time
PRESENTERS, CHAIRS, HOSTS and ORGANIZERS
Univ. of Gothenburg
R. A. Dean Consulting
Anka G. Ehrhardt
CHDI Mgmt/CHDI Fnd.
Fdtn for the NIH
Univ. of Cambridge
Univ. of Washington
Univ. of Edinburgh
Univ. of Utah
Jennifer Rae Myers
The Rockefeller Univ.
Thanaphong (Joe) Phongpreecha
Sheba Med Ctr
Boston Child’s Hosp.
Peter van Vijngaarden
Ctr for Eye Rsrch
Chinese Univ. of HK
Univ. of Gothenburg
Kristina Malzbender, MPH cand., Gates Ventures
Shobha Purushothama, PhD, Alzheimer’s Drug Discovery Foundation
Nico Stanculescu, MS, World Events Forum
Aishwarya Sukumar, MBA/MPH cand., Gates Ventures
We are grateful for the generosity of donors that made possible the Diagnostics Accelerator Initiative:
Charles and Helen Schwab Foundation
Leonard A. Lauder
The Association for Frontotemporal Degeneration
The Dolby Family
The Diagnostics Accelerator would like to acknowledge the following for generously sharing their time, knowledge and expertise to shape our portfolio:
Diagnostics Accelerator Core Team
Joint Steering Committee
Sample Sharing Program Partners
ADDF Grants and Mission Related Investment Team
ADDF Communications Team
ADDF Science Team